{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T09:27:05Z","timestamp":1789896425750,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM103392"],"award-info":[{"award-number":["GM103392"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["AG040217"],"award-info":[{"award-number":["AG040217"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["AR061932"],"award-info":[{"award-number":["AR061932"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["AR067858"],"award-info":[{"award-number":["AR067858"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK095143"],"award-info":[{"award-number":["DK095143"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008955","name":"Maine Medical Center Research Institute","doi-asserted-by":"publisher","award":["GM106391"],"award-info":[{"award-number":["GM106391"]}],"id":[{"id":"10.13039\/100008955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.bone.2017.07.008","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T03:02:01Z","timestamp":1499310121000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice"],"prefix":"10.1016","volume":"103","author":[{"given":"Katherine J.","family":"Motyl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Beauchemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong T.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Treyball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Contractor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Houseknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bone.2017.07.008_bb0005","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/jama.2013.276603","article-title":"Efforts stall to curb nursing home antipsychotic use","volume":"310","author":"Kuehn","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.bone.2017.07.008_bb0010","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.bone.2017.07.008_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","article-title":"Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents","volume":"19","author":"Calarge","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.bone.2017.07.008_bb0020","article-title":"Risperidone versus other atypical antipsychotics for schizophrenia","volume":"1","author":"Komossa","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1\u20133","key":"10.1016\/j.bone.2017.07.008_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","article-title":"Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study","volume":"111","author":"Patel","year":"2009","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.bone.2017.07.008_bb0030","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes A","year":"2004","journal-title":"Diabetes Care"},{"issue":"2\u20133","key":"10.1016\/j.bone.2017.07.008_bb0035","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.schres.2014.09.032","article-title":"The risks of major osteoporotic fractures in patients with schizophrenia: a population-based 10-year follow-up study","volume":"159","author":"Tsai","year":"2014","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.bone.2017.07.008_bb0040","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2165\/00023210-200721080-00003","article-title":"Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation","volume":"21","author":"Halbreich","year":"2007","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.bone.2017.07.008_bb0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4088\/JCP.08m04595gre","article-title":"A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys","volume":"71","author":"Calarge","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.bone.2017.07.008_bb0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","article-title":"Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients","volume":"64","author":"Becker","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.bone.2017.07.008_bb0055","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4088\/JCP.v68n0616","article-title":"Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study","volume":"68","author":"Liperoti","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"13","key":"10.1016\/j.bone.2017.07.008_bb0060","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.22679","article-title":"Atypical antipsychotic use and risk of fracture in persons with Parkinsonism","volume":"24","author":"Dore","year":"2009","journal-title":"Mov. Disord."},{"issue":"1\u20133","key":"10.1016\/j.bone.2017.07.008_bb0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.schres.2007.01.013","article-title":"Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables","volume":"93","author":"Meaney","year":"2007","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.bone.2017.07.008_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4088\/JCP.v69n0307","article-title":"Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia","volume":"69","author":"Kishimoto","year":"2008","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.bone.2017.07.008_bb0075","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jgs.12216","article-title":"Fracture risk in nursing home residents initiating antipsychotic medications","volume":"61","author":"Rigler","year":"2013","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.bone.2017.07.008_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2014.6930","article-title":"Falls and fractures with atypical antipsychotic medication use: a population-based cohort study","author":"Fraser","year":"2015","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.bone.2017.07.008_bb0085","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ajhp\/57.3.238","article-title":"Atypical antipsychotic agents: a critical review","volume":"57","author":"Worrel","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.bone.2017.07.008_bb0095","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1517\/14740338.2016.1167873","article-title":"Relationship between antipsychotic medication, serum prolactin levels and osteoporosis\/osteoporotic fractures in patients with schizophrenia: a critical literature review","volume":"15","author":"De Hert","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.bone.2017.07.008_bb0100","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.euroneuro.2015.04.007","article-title":"Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice","volume":"25","author":"Pacchiarotti","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.bone.2017.07.008_bb0105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bone.2011.08.005","article-title":"Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain","volume":"50","author":"Motyl","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2017.07.008_bb0110","doi-asserted-by":"crossref","DOI":"10.1210\/en.2015-1099","article-title":"Propranolol attenuates risperidone-induced trabecular bone loss in female mice","author":"Motyl","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2017.07.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-011-9505-1","article-title":"VDR haploinsufficiency impacts body composition and skeletal acquisition in a gender-specific manner","author":"de Paula","year":"2011","journal-title":"Calcif. Tissue Int."},{"issue":"6","key":"10.1016\/j.bone.2017.07.008_bb0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2017.07.008_bb0130","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/jcb.21083","article-title":"Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype","volume":"100","author":"Irwin","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bone.2017.07.008_bb0135","doi-asserted-by":"crossref","first-page":"15020","DOI":"10.1038\/boneres.2015.20","article-title":"Dopaminergic effects on in vitro osteogenesis","volume":"3","author":"Lee","year":"2015","journal-title":"Bone Res."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2013.04.019","article-title":"Dopamine D2-like receptor signaling suppresses human osteoclastogenesis","volume":"56","author":"Hanami","year":"2013","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2017.07.008_bb0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2009.06.051","article-title":"A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure","volume":"138","author":"Yadav","year":"2009","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bone.2017.07.008_bb0150","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/nm.4166","article-title":"Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect","volume":"22","author":"Ortuno","year":"2016","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bone.2017.07.008_bb0155","first-page":"R138","article-title":"Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with type 2 diabetes","volume":"306","author":"Zheng","year":"2014","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S8756-3282(99)00232-X","article-title":"Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene","volume":"26","author":"Bliziotes","year":"2000","journal-title":"Bone"},{"issue":"1\u20133","key":"10.1016\/j.bone.2017.07.008_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2003.08.100","article-title":"Reduced dopaminergic tone in hypothalamic neural circuits: expression of a \u201cthrifty\u201d genotype underlying the metabolic syndrome?","volume":"480","author":"Pijl","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bone.2017.07.008_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.alcohol.2014.09.034","article-title":"Circadian clock genes: effects on dopamine, reward and addiction","volume":"49","author":"Parekh","year":"2015","journal-title":"Alcohol"},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","article-title":"Insulin resistance impairs nigrostriatal dopamine function","volume":"231","author":"Morris","year":"2011","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0190","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13075-017-1290-4","article-title":"Prolactin blocks the expression of receptor activator of nuclear factor kappaB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis","volume":"19","author":"Ledesma-Colunga","year":"2017","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.bone.2017.07.008_bb0195","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/endo.140.1.6436","article-title":"Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice","volume":"140","author":"Clement-Lacroix","year":"1999","journal-title":"Endocrinology"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821730234X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821730234X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:38:59Z","timestamp":1762659539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821730234X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":39,"alternative-id":["S875632821730234X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2017.07.008","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2017.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}